SCHEMBL2930581

SCHEMBL2930581

Fc1ccc(-c2nc3[nH]ncc3c(-c3cnc[nH]3)c2-c2ccncc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPK14 Q16539 16/20 0.40
MAPK11 Q15759 7/20 0.40
MAPK13 O15264 5/20 0.40
MAPK12 P53778 5/20 0.40
MAPK9 P45984 2/20 0.40
RAF1 P04049 2/20 0.40
KIT P10721 1/20 0.40
MAPK10 P53779 1/20 0.37
CSNK1D P48730 2/20 0.37
GSK3B P49841 2/20 0.37
PRKD3 O94806 1/20 0.37
MAP4K4 O95819 1/20 0.37
FRK P42685 1/20 0.37
GCGR P47871 1/20 0.37
CSNK1A1 P48729 1/20 0.37
PTK6 Q13882 1/20 0.37
PRKD2 Q9BZL6 1/20 0.37
CLK4 Q9HAZ1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931861 0.88 MAPK14 (0.48) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL29652689 0.88 MAPK14 (0.48) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL1386446 0.82 MAPK14 (0.49) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL2929750 0.80 MAPK14 (0.40) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL1386922 0.80 ADORA1 (0.46) SMN1; SMN2MAPK14MAPK11MAPK13MAPK12
SCHEMBL1384646 0.79 MAPK14 (0.40) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL2929925 0.79 MAPK14 (0.40) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL1386461 0.77 MAPK14 (0.53) SMN1; SMN2MAPK14MAPK11MAPK13MAPK12
SCHEMBL1386904 0.77 MAPK14 (0.53) MAPK14MAPK11MAPK13MAPK12MAPK9
SCHEMBL1384940 0.77 KDM4E (0.41) MAPK14MAPK11MAPK13MAPK12MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 POLB 2061/4885SMN1; SMN2 3262/4885MAPK14 34/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 POLB 1945/4885SMN1; SMN2 3438/4885MAPK14 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.